Literature DB >> 25790347

Successful topical rapamycin treatment for facial angiofibromata in two children.

Emma V Pynn1, Jemma Collins1, Prasad R Y Hunasehally2, Jenny Hughes2.   

Abstract

Topical sirolimus, or rapamycin, is known to inhibit tumorigenesis in tuberous sclerosis. We report two cases of successful treatment of children with facial angiofibromata and summarize the encouraging evidence of the effectiveness of this therapy in the literature.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25790347     DOI： 10.1111/pde.12551

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN： 0736-8046            Impact factor:   1.588


  4 in total

1.  Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.

Authors:  Mary Kay Koenig; Cynthia S Bell; Adelaide A Hebert; Joan Roberson; Joshua A Samuels; John M Slopis; Patti Tate; Hope Northrup
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

2.  A 28-Year-Old Male Patient with Nail Tumors, Skin Lesions, and Epilepsy.

Authors:  Deepak M W Balak; Bernard A Zonnenberg; Juliette M J Spitzer-Naaijkens; Mieke M Hulshof
Journal:  Case Rep Dermatol       Date:  2017-01-26

3.  Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up.

Authors:  Daniel Ebrahimi-Fakhari; Cornelia Sigrid Lissi Müller; Sascha Meyer; Marina Flotats-Bastardas; Thomas Vogt; Claudia Pföhler
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-08

4.  Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed.

Authors:  Guillaume Le Guyader; Bernard Do; Victoire Vieillard; Karine Andrieux; Muriel Paul
Journal:  Pharmaceutics       Date:  2020-11-07       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.